Adenovirus Vaccine Shortfall: Impact on Readiness and Deployability

Abstract

Vaccines enhance our national defense by protecting the health of men and women who serve their nation in uniform. In 1995, Wyeth Laboratories, the sole licensed manufacturer of the adenovirus vaccines, ceased production for economic reasons. Department of Defense was forewarned of Wyeth's problems in meeting the military's need for these vaccines, but in 1984 the Pentagon denied a request from Wyeth for five million dollars to upgrade its facility to meet regulatory standards. That decision resulted in the complete loss of adenovirus vaccine production. This paper assesses the impact of the shortfall of the adenovirus vaccine on training, readiness, deployability, and the military health care system; and examines the cost of procuring a new manufacturer for the vaccine.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 13, 2001
Accession Number
ADA403017

Entities

People

  • Niranjan Balliram

Organizations

  • United States Army War College

Tags

DTIC Thesaurus Topics

  • Basic Training
  • Cost Benefit Analysis
  • Cost Effectiveness
  • Disease Outbreaks
  • Environmental Protection
  • Health Care
  • Health Services
  • Infectious Diseases
  • Medical Personnel
  • Military Medicine
  • Military Training
  • Respiratory Tract Diseases
  • Students
  • Trainees
  • United States
  • Viruses
  • War Colleges

Readers

  • Infectious Disease/Epidemiology
  • Military History of the United States in the 20th Century.
  • Military Training and Readiness Simulation

Technology Areas

  • Biotechnology